Abstract Body

Background: Two phase 3, randomized, blinded, studies of elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) in treatment-naïve subjects are ongoing (Studies 102 and 103). The week (W) 144 responses (Missing = Failure) were durable and similar for EVG/COBI/FTC/TDF vs. efavirenz ([EFV]/FTC/TDF) (82% vs 78%) and EVG/COBI/FTC/TDF vs. ritonavir-boosted atazanavir (ATV+RTV)+FTC/TDF (81% vs 79%). Resistance analyses through W144 are presented. Methodology: HIV-1 genotypes (PR and RT) were analyzed at screening (GeneSeq, Monogram Biosciences); subjects with resistance to FTC, TDF, EFV, or ATV were excluded based on study. Retrospective integrase (IN) genotyping was conducted on 363 EVG/COBI/FTC/TDF baseline samples. Virologic failures had genotypic/phenotypic analyses at confirmed failure and baseline for PR, RT, and IN, or at first failure (EVG/COBI/FTC/TDF only) (Monogram and Labcorp). Results: EVG/COBI/FTC/TDF subjects with baseline PI (N=18) or NNRTI mutations (N=95) including K103N in RT (N=27, Study 103) had high virologic response through W144 (82% for K103N). Baseline primary IN strand transfer inhibitor (INSTI) mutations were rare (N=4/337); all EVG/COBI/FTC/TDF subjects with T97A [N=3] and Y143H [N=1] rapidly suppressed and had W144 HIV-1 RNA <50 c/ml. In the EVG/COBI/FTC/TDF groups through W144, 18 subjects (2.6%; 18/701) developed primary INSTI (N=15) and/or NRTI resistance mutations (N=17) (Any resistance: 13 through W48, 3 between W48-W96, and 2 between W96-W144). Emergent INSTI mutations were E92Q (N=9), N155H (N=5), Q148R (N=3), T66I (N=2) and T97A (N=1) and emergent NRTI mutations were M184V/I (N=17) and K65R (N=5). In the EFV/FTC/TDF group, 14 subjects (4.0%; 14/352) developed drug resistance (8 through W48, 2 between W48-W96, and 4 between W96-W144) and was most commonly K103N (N=13) with M184V/I (N=4) plus K65R (N=3) in RT. In the ATV+RTV+FTC/TDF group, 2 subjects had M184I emerge post-W96. The first failure samples from 16 STB patients with emergent resistance were retrospectively analyzed and failed to detect the known resistance in >50% of these patients due to either assay failures or successful genotypes in which no resistance was detected (N=5/16). Conclusions: Treatment with EVG/COBI/FTC/TDF achieved durable high rates of virologic suppression in HIV-1 treatment-naive subjects, including subjects with pre-existing NNRTI or PI resistance. Resistance development was infrequent (2.6% of STB-treated subjects). The most common patterns of resistance mutations to EVG/COBI/FTC/TDF were E92Q, Q148R, or N155H in IN with M184V/I in RT which were more readily detected at the confirmed virologic failure timepoint.